Zwitterionic Supramolecular Nanoassemblies With siRNA and Simvastatin as “Nanoscavenger” for Synergistic Atherosclerosis Treatment
Small · 2025
DOI: 10.1002/smll.202506957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Weihong Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomaterials and Tissue Engineering, Fujian Provincial Key Laboratory of Biochemical Technology, College of Chemical Engineering, Huaqia…. Hauptthemen laut MEDLINE: Simvastatin, Atherosclerosis, RNA, Small Interfering, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Natural Science Foundation of Xiamen, China, Fundamental Research Funds for the Central Universities, Scientific Research Funds of Huaqiao University.
Abstract (Originalsprache)
Atherosclerotic vulnerable plaques contain various undesirable components, including excess cholesterol, efferocytosis‐deficient macrophages, and inflammatory factors. However, conventional lipid‐lowering drugs often show limited efficacy due to their inability to target the complex pathophysiology. Herein, innovative zwitterionic supramolecular nanoassemblies, termed PCDSC‐S2P, are developed as the nanoscavenger to reduce and stabilize plaques. The nanoassemblies are based on zwitterionic poly(carboxybetaine)‐modified β‐cyclodextrin (β‐CD) acting as a host molecule that encapsulates simvastatin (Sim) as a guest and absorbs small interfering RNA targeting calcium/calmodulin‐dependent protein kinase II gamma (siCaMKIIγ) electrostatically. The PCDSC‐S2P nanoassemblies are driven by host‐guest interactions, electrostatic interactions, and hydrogen bonds. Moreover, the macrophage‐targeting peptide modification directs nanoassemblies accumulation toward atherosclerotic plaques. Therefore, PCDSC‐S2P, as the nanoscavenger, can act at the lesional plaque via β‐CD‐mediated cholesterol removal, Sim‐driven lipid lowering, and siCaMKIIγ‐enhanced efferocytosis synergistically. Consequently, the PCDSC‐S2P treatment regulates the release of inflammatory cytokines and exhibits anti‐inflammatory activity. Furthermore, PCDSC‐S2P can significantly reduce plaque area and stabilize plaques in apolipoprotein E‐deficient mice fed with a high‐fat diet. Together, PCDSC‐S2P shows great potential as a new delivery system in the development of small interfering RNA formulation, showing its promise for atherosclerosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomaterials and Tissue Engineering, Fujian Provincial Key Laboratory of Biochemical Technology, College of Chemical Engineering, Huaqiao University, Xiamen, Fujian, 361021, P. R. China.
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
ORCID-Profile: Weihong Ji, Xin Zhang
Förderung
- Natural Science Foundation of Xiamen, China
- Fundamental Research Funds for the Central Universities
- Scientific Research Funds of Huaqiao University
- National Natural Science Foundation of China
Zitieren
APA
Ji, W., Shao, W., Ye, X., Kankala, R. K., Chen, A., & Zhang, X. (2025). Zwitterionic Supramolecular Nanoassemblies With siRNA and Simvastatin as “Nanoscavenger” for Synergistic Atherosclerosis Treatment. Small. https://doi.org/10.1002/smll.202506957
Vancouver
Ji W, Shao W, Ye X, Kankala RK, Chen A, Zhang X. Zwitterionic Supramolecular Nanoassemblies With siRNA and Simvastatin as “Nanoscavenger” for Synergistic Atherosclerosis Treatment. Small. 2025. doi:10.1002/smll.202506957
BibTeX
@article{Ji2025,
author = {Ji, Weihong and Shao, Weichen and Ye, Xing and Kankala, Ranjith Kumar and Chen, Aizheng and Zhang, Xin},
title = {Zwitterionic Supramolecular Nanoassemblies With siRNA and Simvastatin as “Nanoscavenger” for Synergistic Atherosclerosis Treatment},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202506957}
}
EUVIMED